

2025 Society for NeuroOncology Annual Meeting



📅 Saturday, November 22, 2025


🕒 11:45am - 1:05pm HST

Title: Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with temozolomide or radiation

Lead Author: Katelyn Willis

Abstract: EXTH-100

Poster presentation Saturday, November 22, 2025

 [SNO 2025_INBRX-109 GBM Preclinical Data](#)
(1.8 MB)

<https://inhibrxbiosciences.investorroom.com/events-and-presentations?item=53>